Patents by Inventor Lingyun Rui

Lingyun Rui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160060339
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: August 5, 2015
    Publication date: March 3, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Novel EGFR-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20160060345
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: August 7, 2015
    Publication date: March 3, 2016
    Inventors: Julianto SETIADY, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20160017053
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: May 8, 2015
    Publication date: January 21, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Julianto SETIADY, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
    Patent number: 9238690
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: January 19, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • CD20 antibodies and uses thereof
    Patent number: 9173961
    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 3, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Lingyun Rui, Peter U. Park
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9133275
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 15, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • EGFR-binding molecules and immunoconjugates thereof
    Patent number: 9125896
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 8, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Antibodies and Assays for Detection of Folate Receptor 1
    Publication number: 20150093388
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 2, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • EGFR-binding molecules and immunoconjugates thereof
    Patent number: 8790649
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 29, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • CD37-binding molecules and immunoconjugates thereof
    Patent number: 8765917
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: July 1, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
    Publication number: 20140023662
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: October 28, 2011
    Publication date: January 23, 2014
    Applicant: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • CD37-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20130295104
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: March 12, 2013
    Publication date: November 7, 2013
    Inventors: Jutta DECKERT, Peter Park, Daniel Tavares, Lingyun Rui
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20130295119
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 7, 2013
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmaker
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 8557966
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: October 15, 2013
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Novel EGFR-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20120156217
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: October 28, 2011
    Publication date: June 21, 2012
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20120009181
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: February 24, 2011
    Publication date: January 12, 2012
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • CD37-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20110256153
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: March 11, 2011
    Publication date: October 20, 2011
    Inventors: Jutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
  • CD20 ANTIBODIES AND USES THEREOF
    Publication number: 20110195021
    Abstract: CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
    Type: Application
    Filed: February 10, 2011
    Publication date: August 11, 2011
    Applicant: IMMUNOGEN INC.
    Inventors: Jutta DECKERT, Lingyun Rui, Peter U. Park